

# Memorandum

To: All Participating Dementia Practices and PET Imaging Facilities

From: New IDEAS Study Leadership

Date: December 12, 2023

Subject: Updated Billing Guidance for New IDEAS Amyloid PET Scans

The New IDEAS Study protocol was initially approved as a Coverage with Evidence Development (CED) Study under the supervision of the Centers for Medicare & Medicaid Services (CMS). On October 13, 2023, CMS issued a [public announcement](#) that retired the National Coverage Determination (NCD) on amyloid PET and ended CED as a criterion for coverage of amyloid PET scans. As a result of the retirement of the NCD, the CED is no longer applicable to the New IDEAS Study. Local Medicare contractors (MACs) now have authority to make coverage determinations for PET beta-amyloid imaging for dementia and neurodegenerative disease. In response to the NCD retirement, CMS released updated billing guidance for imaging facilities for scans. Please review the following billing guidelines:

- **For all New IDEAS amyloid PET scans completed on or after October 13, 2023, submitted claim forms should adhere to the following guidance to ensure proper reimbursement from Medicare:**
  - o The study's NCT number should not be listed in box 19.
  - o The Q0 modifier should not be listed in box 24.
  - o All HCPCS/CPT codes should remain the same as typically used.
  - o Any claims that get rejected should be brought to the Study's attention for additional guidance and support.
    - Providers and/or billing and coding staff are also encouraged to [contact their MAC](#) to clarify billing requirements, as needed.
- These changes do not impact the participating practice. Practices should continue to use standard clinical ICD-10 codes.
- Imaging Facilities: Please review the following transmittals and MLN articles regarding NCD 220.6.20 - Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease ([Transmittal R12364CP](#) and [R12364NCD](#) and [MM13429](#)).
- Review [New IDEAS Sample Claims Forms](#) for specific facility billing guidance.

## Important reminders:

- The New IDEAS Study remains active and is enrolling new patients.
- The [New IDEAS Coinsurance Reimbursement Program](#) remains active and in effect.
- Any additional billing guidance will be disseminated by the Study Team when available.
- Please notify the New IDEAS Operations Team if your practice or facility experiences any problems with coverage of amyloid PET scans for patients enrolled in New IDEAS.

Study leadership commends the active dementia practices and imaging facilities for their continued enthusiasm and commitment to the New IDEAS Study. All questions related to this memo should be directed to the study's operational team at [newideas@acr.org](mailto:newideas@acr.org).